Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – NIH chronic GVHD Consortium

Drs. Steven Pavletic and Matin Imanguli, both clinicians in CCR’s Experimental Transplantation and Immunology Branch, led the effort to create a trans-NIH consortium focusing on chronic Graft versus Host Disease (GVHD), a common and serious complication of allogeneic bone marrow transplantation. In GVHD immune cells in the transplanted bone marrow mistakenly recognize the recipient (i.e., patient) as “foreign” and begin to aggressively attack the patient’s immune system. GVHD may damage organs such as the liver, skin and mucosa, and the gastrointestinal tract, while chronic GVHD may also damage the connective tissue.

Established in 2003 with the goal of creating a high-quality, multidisciplinary clinical and research program at the NIH, the chronic GVHD Consortium today is a dynamic, interdisciplinary collaboration with members from 10 NIH Institutes. The Consortium is focused on 1) developing a trans-NIH chronic GVHD clinic; 2) developing standard GVHD evaluation tools; 3) conducting pathophysiology studies of GVHD; 4) developing new treatments for GVHD patients; and 5) providing regional, national, and international leadership in this field. To learn more, visit NIH Chronic Graft versus Host Disease Study Group.

To learn more, visit NIH Chronic Graft versus Host Disease Study Group

More Initiatives

Diagnostic Imaging

Microarrays

Molecular Targets

Nanotechnology